- Home
- WWR vs CALC Comparison
WWR vs CALC Comparison
Compare WWR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- CALC
- Stock Information
- Founded
- WWR 1977
- CALC 2011
- Country
- WWR United States
- CALC United States
- Employees
- WWR N/A
- CALC N/A
- Industry
- WWR Metal Mining
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- CALC Health Care
- Exchange
- WWR Nasdaq
- CALC Nasdaq
- Market Cap
- WWR 48.0M
- CALC 48.1M
- IPO Year
- WWR N/A
- CALC N/A
- Fundamental
- Price
- WWR $0.76
- CALC $3.20
- Analyst Decision
- WWR Strong Buy
- CALC Strong Buy
- Analyst Count
- WWR 2
- CALC 2
- Target Price
- WWR $2.00
- CALC $14.50
- AVG Volume (30 Days)
- WWR 1.2M
- CALC 73.7K
- Earning Date
- WWR 11-14-2025
- CALC 11-12-2025
- Dividend Yield
- WWR N/A
- CALC N/A
- EPS Growth
- WWR N/A
- CALC N/A
- EPS
- WWR N/A
- CALC N/A
- Revenue
- WWR N/A
- CALC N/A
- Revenue This Year
- WWR N/A
- CALC N/A
- Revenue Next Year
- WWR N/A
- CALC N/A
- P/E Ratio
- WWR N/A
- CALC N/A
- Revenue Growth
- WWR N/A
- CALC N/A
- 52 Week Low
- WWR $0.45
- CALC $1.42
- 52 Week High
- WWR $1.32
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- WWR 56.01
- CALC 54.05
- Support Level
- WWR $0.66
- CALC $2.62
- Resistance Level
- WWR $0.82
- CALC $3.73
- Average True Range (ATR)
- WWR 0.05
- CALC 0.35
- MACD
- WWR -0.00
- CALC -0.01
- Stochastic Oscillator
- WWR 62.50
- CALC 52.25
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.